Peptides for Heart health
The peptides people most often research for heart health, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 6
- With human trials
- 4
- FDA approved (any use)
- 3
- BPC-157Gastric pentadecapeptideAnimal evidence, 2 of 4Biomedicines 2022, PMID 35203478Human3Animal5Summarised1PCAC voted 8–6 for 503A (Jul 2026)For heart healthOverview
- TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 41406444Human358Animal11Summarised7FDA approved (Mounjaro, Zepbound)For heart healthOverview
- RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4Diabetes, obesity & metabolism 2026, PMID 42608321Human23Animal0Summarised3Investigational · phase 3For heart healthOverview
- SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4American heart journal 2025, PMID 40345413Human906Animal38Summarised8FDA approved (Ozempic, Wegovy, Rybelsus)For heart healthOverview
- HGHRecombinant growth hormoneHuman RCT evidence, 4 of 4Clinical endocrinology 1998, PMID 10197085Human856Animal125Summarised4FDA approved (prescription only)For heart healthOverview
- IpamorelinGHRP (ghrelin receptor agonist)No study with an outcome for heart healthPubMed search, 11 Oct 2026Human2Animal0Summarised0Not FDA approved · research chemicalOverview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What heart disease covers
MedlinePlus calls heart disease a general term that includes many types of heart problems.[9]
It names coronary artery disease as the most common type.[9]
Outcome trials are concentrated in GLP-1 drugs
Semaglutide has 906 human-only papers and 89 randomised trials for heart outcomes and tirzepatide 358 and 30, while BPC-157 has 3 human-only and 5 animal papers and ipamorelin has 2 human-only.
Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); bpc-157 human only 3, animal only 5, rct 0; tirzepatide human only 358, animal only 11, rct 30; retatrutide human only 23, animal only 0, rct 1; semaglutide human only 906, animal only 38, rct 89; hgh human only 856, animal only 125, rct 141; ipamorelin human only 2, animal only 0, rct 0. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.
A cardiovascular outcomes trial of semaglutide in people with overweight or obesity and heart disease found fewer primary events than placebo.[10]
A tirzepatide trial in heart failure with preserved ejection fraction found fewer cardiovascular deaths or worsening heart-failure events than placebo.[11]
A tirzepatide-versus-dulaglutide outcomes trial reported noninferiority for major events, though the hazard ratio did not reach superiority.[2]
In a trial of recombinant thymosin beta-4 for heart attack, differences in infarct area versus placebo were not significant (n = 96).[12]
In a randomised study of patients with heart failure with reduced ejection fraction, SS-31 at the highest dose cohort significantly decreased left ventricular end-diastolic volume (-18 mL) and end-systolic volume (-14 mL) versus placebo.[13]
BPC-157 data are in rats, where it reduced myocardial infarction markers.[1]
What the Wegovy label says about heart risk
Wegovy is labelled to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, alongside diet and activity changes.[14]
Common questions
What are the best peptides for heart health?
Among the listed peptides, semaglutide has a randomised cardiovascular outcomes trial in which a primary event occurred in 6.5% of the semaglutide group against 8.0% on placebo.[10]
Do heart peptides work?
In the cached sources, thymosin beta-4 showed no significant difference in infarct area versus placebo in people (n = 96). BPC-157's cardiac data here are from rats.[12]
Is there a best peptide for heart health?
The one head-to-head outcomes trial in the evidence files compared tirzepatide with dulaglutide, not with a research peptide. A primary event occurred in 12.2% against 13.1%.[2]
Is any peptide FDA approved to lower heart attack risk?
Wegovy's label includes an indication to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.[14]
Explore nearby goals
Sources
- 1Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.Biomedicines · 2022PMID 35203478Accessed 2 Oct 2026
- 2Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
- 3Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 4Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
- 5HDL-cholesterol reductions associated with adult growth hormone replacement.Clinical endocrinology · 1998PMID 10197085Accessed 2 Oct 2026
- 6PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 9Official web pageOfficial web page · web page
- 10Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026
- 11Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.The New England journal of medicine · 2025PMID 39555826Accessed 2 Oct 2026
- 12Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
- 13Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.Circulation. Heart failure · 2017PMID 29217757Accessed 2 Oct 2026
- 14WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.